$290 Million is the total value of Sarissa Capital Management LP's 15 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARIA | ARIAD PHARMACEUTICALS INC | $96,720,000 | +18.2% | 12,000,000 | 0.0% | 33.30% | +8.7% | |
| DGX | Buy | QUEST DIAGNOSTICS INC | $44,888,000 | +19.8% | 775,000 | +10.7% | 15.46% | +10.1% |
| BRLI | Buy | BIO-REFERENCE LABS INC | $35,458,000 | +386.6% | 1,280,984 | +349.0% | 12.21% | +347.4% |
| IDIX | IDENIX PHARMACEUTICALS INC | $30,452,000 | +0.8% | 5,050,100 | 0.0% | 10.48% | -7.3% | |
| MRK | MERCK & CO INC NEW | $22,708,000 | +13.4% | 400,000 | 0.0% | 7.82% | +4.3% | |
| MNKKQ | Sell | MALLINCKRODT PUB LTD CO | $17,431,000 | +19.1% | 274,895 | -1.8% | 6.00% | +9.5% |
| VVUS | VIVUS INC | $15,289,000 | -34.6% | 2,573,943 | 0.0% | 5.26% | -39.9% | |
| RPRX | Buy | REPROS THERAPEUTICS INC | $9,945,000 | +18.3% | 560,600 | +22.0% | 3.42% | +8.7% |
| AVEO | AVEO PHARMACEUTICALS | $3,843,000 | -18.8% | 2,570,759 | 0.0% | 1.32% | -25.3% | |
| LH | New | LABORATORY CORP AMER HLDGS | $3,715,000 | – | 37,824 | +100.0% | 1.28% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $2,303,000 | – | 126,695 | +100.0% | 0.79% | – |
| ONTX | New | ONCONOVA THERAPEUTICS INC | $2,219,000 | – | 350,000 | +100.0% | 0.76% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $2,000,000 | – | 50,000 | +100.0% | 0.69% | – |
| KIN | New | KINDRED BIOSCIENCES INC | $1,887,000 | – | 101,825 | +100.0% | 0.65% | – |
| TRGT | New | TARGACEPT INC | $1,565,000 | – | 329,516 | +100.0% | 0.54% | – |
| PFE | Exit | PFIZER INC | $0 | – | -410,000 | -100.0% | -4.70% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -250,000 | -100.0% | -4.94% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -250,000 | -100.0% | -4.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.